Stifel Nicolaus reaffirmed their hold rating on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research report report published on Wednesday, AnalystRatings.com reports.
“We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new” news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case” scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk.”,” the firm’s analyst wrote.
Several other analysts have also recently commented on the company. BidaskClub cut Aimmune Therapeutics from a buy rating to a hold rating in a research report on Saturday, August 24th. Credit Suisse Group assumed coverage on Aimmune Therapeutics in a research report on Tuesday, May 21st. They issued an outperform rating and a $30.00 target price for the company. ValuEngine raised Aimmune Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. Royal Bank of Canada decreased their target price on Aimmune Therapeutics to $50.00 and set an outperform rating for the company in a research report on Friday, August 9th. Finally, Wedbush set a $79.00 price objective on Aimmune Therapeutics and gave the stock a buy rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $41.38.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.93) by ($0.08). During the same period last year, the business earned ($0.91) earnings per share. As a group, sell-side analysts predict that Aimmune Therapeutics will post -4 earnings per share for the current year.
Several large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of Aimmune Therapeutics by 11.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock worth $109,234,000 after acquiring an additional 535,072 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Aimmune Therapeutics by 4.6% during the second quarter. Vanguard Group Inc. now owns 3,706,394 shares of the biotechnology company’s stock worth $77,167,000 after acquiring an additional 164,038 shares in the last quarter. FMR LLC raised its holdings in shares of Aimmune Therapeutics by 30.3% during the first quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock worth $61,117,000 after acquiring an additional 635,362 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Aimmune Therapeutics by 2.4% during the second quarter. Victory Capital Management Inc. now owns 1,121,811 shares of the biotechnology company’s stock worth $23,357,000 after acquiring an additional 26,690 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in shares of Aimmune Therapeutics by 31.1% during the second quarter. Rice Hall James & Associates LLC now owns 669,560 shares of the biotechnology company’s stock worth $13,940,000 after acquiring an additional 158,851 shares in the last quarter. Institutional investors and hedge funds own 78.06% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Further Reading: What is total return in investing?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.